Impact of breast cancer and combination chemotherapy on oxidative stress, hepatic and cardiac markers

Journal of Breast Cancer

Volumn 15, Issue 3, 2012, Pages 306-312

  Amin, Kamal Adel ^a   Mohamed, Basant Mahmoud ^b   El Wakil, Mohamed Aly M ^c   Ibrahem, Sanaa Omar ^b  

^a Beni Suef University   (Egypt)

^b Beni Suef University   (Egypt)

^c BENI SUEF UNIVERSITY   (Egypt)

Author keywords

Breast neoplasms; Cardiac function; Chemotherapy; Liver function; Oxidative stress

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BIOLOGICAL MARKER; CATALASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GLUTATHIONE; MALONALDEHYDE; NITRIC OXIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD LEVEL; BREAST CANCER; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG EFFECT; FEMALE; HEART FUNCTION TEST; HEART INJURY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LIPID PEROXIDATION; LIVER FUNCTION TEST; MULTIPLE CYCLE TREATMENT; OXIDATIVE STRESS; PATHOGENESIS; URIC ACID BLOOD LEVEL; VOMITING;

EID: 84867689134     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2012.15.3.306     Document Type: Article

References (30)

1. Polyak K. On the birth of breast cancer. Biochim Biophys Acta 2001; 1552:1-13.
2. Gönenç A, Erten D, Aslan S, Akinci M, Simşek B, Torun M. Lipid peroxidation and antioxidant status in blood and tissue of malignant breast tumor and benign breast disease. Cell Biol Int 2006;30:376-80.
3. Yeh CC, Hou MF, Tsai SM, Lin SK, Hsiao JK, Huang JC, et al Superoxide anion radical, lipid peroxides and antioxidant status in the blood of patients with breast cancer. Clin Chim Acta 2005;361:104-11.
4. Kang DH. Oxidative stress, DNA damage, and breast cancer. AACN Clin Issues 2002;13:540-9.
5. Birnboim HC. DNA strand breakage in human leukocytes exposed to a tumor promoter, phorbol myristate acetate. Science 1982;215:1247-9.
6. Matés JM, Sánchez-Jiménez FM. Role of reactive oxygen species in apoptosis: implications for cancer therapy. Int J Biochem Cell Biol 2000; 32:157-70.
7. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992;19:670-86.
8. Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther 2004;3:294-300.
9. Simůnek T, Stérba M, Popelová O, Adamcová M, Hrdina R, Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009; 61:154-71.
10. Rajneesh CP, Manimaran A, Sasikala KR, Adaikappan P. Lipid peroxidation and antioxidant status in patients with breast cancer. Singapore Med J 2008;49:640-3.
11. Cohen G, Dembiec D, Marcus J. Measurement of catalase activity in tissue extracts. Anal Biochem 1970;34:30-8.
12. Beutler E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. J Lab Clin Med 1963;61:882-8.
13. Miranda KM, Espey MG, Wink DA. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001;5:62-71.
14. Satoh K. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin Chim Acta 1978;90:37-43.
15. Burtis CA, Ashwood ER. Tietz Textbook of Clinical Chemistry. 3rd ed. Philadelphia: W.B. Saunders Company; 1998. p.1034.
16. Fossati P, Prencipe L, Berti G. Use of 3,5-dichloro-2-hydroxybenzenesulfonic acid/4-aminophenazone chromogenic system in direct enzymic assay of uric acid in serum and urine. Clin Chem 1980;26:227-31.
17. Acharya A, Das I, Chandhok D, Saha T. Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid Med Cell Longev 2010;3:23-34.
18. Gerhäuser C, Klimo K, Heiss E, Neumann I, Gamal-Eldeen A, Knauft J, et al Mechanism-based in vitro screening of potential cancer chemopreventive agents. Mutat Res 2003;523-524:163-72.
19. Prabasheela B, Singh AK, Fathima A, Pragulbh K, Deka NJ, Kumar R. Association between antioxidant enzymes and breast cancer. Recent Res Sci Technol 2011;3:93-5.
20. Kasapović J, Pejić S, Stojiljković V, Todorović A, Radošević-Jelić L, Saičić ZS, et al Antioxidant status and lipid peroxidation in the blood of breast cancer patients of different ages after chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide. Clin Biochem 2010;43:1287-93.
21. Switzer CH, Glynn SA, Ridnour LA, Cheng RY, Vitek MP, Ambs S, et al Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. Trends Pharmacol Sci 2011; 32:644-51.
22. Ambs S, Glynn SA. Candidate pathways linking inducible nitric oxide synthase to a basal-like transcription pattern and tumor progression in human breast cancer. Cell Cycle 2011;10:619-24.
23. Alshabanah OA, Hafez MM, Al-Harbi MM, Hassan ZK, Al Rejaie SS, Asiri YA, et al. Doxorubicin toxicity can be ameliorated during antioxidant L-carnitine supplementation. Oxid Med Cell Longev 2010;3:428-33.
24. Nohl H. Demonstration of the existence of an organo-specific NADH dehydrogenase in heart mitochondria. Eur J Biochem 1987;169:585-91.
25. Kono Y, Fridovich I. Superoxide radical inhibits catalase. J Biol Chem 1982;257:5751-4.
26. Kaithwas G, Dubey K, Pillai KK. Effect of aloe vera (Aloe barbadensis Miller) gel on doxorubicin-induced myocardial oxidative stress and calcium overload in albino rats. Indian J Exp Biol 2011;49:260-8.
27. Koti BC, Vishwanathswamy AH, Wagawade J, Thippeswamy AH. Cardioprotective effect of lipistat against doxorubicin induced myocardial toxicity in albino rats. Indian J Exp Biol 2009;47:41-6.
28. Goormaghtigh E, Huart P, Praet M, Brasseur R, Ruysschaert JM. Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity. Biophys Chem 1990;35:247-57.
29. Deng S, Kulle B, Hosseini M, Schlüter G, Hasenfuss G, Wojnowski L, et al Dystrophin-deficiency increases the susceptibility to doxorubicininduced cardiotoxicity. Eur J Heart Fail 2007;9:986-94.
30. Nohl H, Gille L, Staniek K. The exogenous NADH dehydrogenase of heart mitochondria is the key enzyme responsible for selective cardiotoxicity of anthracyclines. Z Naturforsch C 1998;53:279-85.